| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (NCT05113537) | Vadim S Koshkin | 2022-07-08 |
| Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer (NCT05479578) | Rashmi Verma, MD | 2022-06-29 |
| Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (NCT04704505) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2022-04-28 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT05168618) | University of Utah | 2022-03-29 |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones (NCT04616547) | National Cancer Institute (NCI) | 2021-12-18 |
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (NCT04455750) | Alliance for Clinical Trials in Oncology | 2021-10-14 |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer (NCT04754425) | M.D. Anderson Cancer Center | 2021-07-15 |
| Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04781374) | Beth Israel Deaconess Medical Center | 2021-05-21 |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (NCT04734730) | City of Hope Medical Center | 2021-05-04 |
| Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer (NCT03902951) | Jonsson Comprehensive Cancer Center | 2021-03-17 |
| ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT04471974) | Rahul Aggarwal | 2021-01-26 |
| Evaluation of PSMA Antagonist Produced by Two Different Methods (NCT04685811) | Weill Medical College of Cornell University | 2020-12-09 |
| Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring (NCT05054296) | M.D. Anderson Cancer Center | 2020-03-23 |
| A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer (NCT04190446) | Mayo Clinic | 2020-01-06 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT04033432) | Northwestern University | 2019-09-20 |
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (NCT03317392) | National Cancer Institute (NCI) | 2019-02-04 |
| Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies (NCT03611686) | University Hospital, Rouen | 2018-04-17 |
| Tumor Molecular Profiling in Patients With Prostate Cancer (NCT05573789) | Hellenic Cooperative Oncology Group | 2018-01-01 |
| Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy (NCT02099864) | OHSU Knight Cancer Institute | 2014-02-05 |